The frontrunners in a crowded race to develop the first vaccine for respiratory syncytial virus (RSV) — pharmaceutical giants Pfizer and GSK — will face scrutiny from a panel of U.S. experts this week.
Frontrunners in RSV vaccine race will face scrutiny from U.S. officials this week
Post a Comment